After Intellia Therapeutics paused a pair of phase 3 trials for its CRISPR therapy in response to a liver safety signal, the ...
Intellia Therapeutics said it is pausing two late-stage CRISPR gene-editing trials after a patient in one study was hospitalized with liver damage.
Intellia Therapeutics recently announced it has paused patient dosing and screening in its Phase 3 MAGNITUDE and MAGNITUDE-2 trials of nex-z for transthyretin amyloidosis following a serious ...
CAMBRIDGE, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, ...
Both CRSP and NTLA are advancing in vivo gene editing therapies targeting large markets, with financial stability supporting ...
Shares of CRISPR Therapeutics CRSP have risen 14% over the past month, likely driven by encouraging results from the first candidates in its in vivo pipeline. CRSP’s Positive In Vivo Therapy Data Last ...
CRISPR Therapeutics has reported reductions in triglycerides and LDL cholesterol of more than 80% after a single dose of its in vivo liver editing prospect CTX310, encouraging the company to forge ...
Clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated (Cas) proteins are core components of fast-evolving therapeutic gene editing tools. Scientists have used CRISPR ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback